The Ntensify™ Production Technology Line is now available!

Ntensify™ are low footprint automated Production Technologies able to synthesize and purify short to very long Messenger RNA's in bulk. Our systems use Quantoom’s reagent pre-mixes to maximize yield, quality, and cost-effectiveness, starting from a chosen DNA template. This produces purified naked RNA, ready to be formulated into a drug product.

Ntensify™ is more than just equipment, it includes:

  • quantoom-icon
    An optimized process for high performance (yield and quality)
  • quantoom-icon
    Reagent premixes to ensure the best results
  • quantoom-icon
    Single use disposables for ease of use

Did you miss our launch webinar? Watch the replay!

white-down-grey
ntensify

Why choose Ntensify™ ?

Our design brings three main benefits to your mRNA program:

  • De-risked development: The Ntensify™ process has been successively optimized over hundreds of Upstream and Downstream reactions with 18 different constructs varying in length from around 1,000 nucleotides (mRNA) to 11,000 nucleotides (samRNA). Today, we dare to say that Ntensify™ delivers above-average  performance both in yield and quality, fit for various types of RNA constructs.
  • Speed to market: Ntensify™ accelerates development during the discovery phase with high throughput candidate screening and through its ability to produce micrograms up to multiple kilograms of RNA drug substance without months of scale-up.
  • Cost-effectiveness: our Ntensify™ Production Technologies give developers significant savings. Our intensification and chaining principles ensure that Ntensify™ has  a very small footprint and the ability to handle smaller volumes than conventional approaches. This reduces size of the production facility and the capital required as well as lowering operating costs due to smaller volumes.
How Ntensify™ was invented

The COVID-19 pandemic demonstrated the power of RNA vaccines. However, the way RNA is synthesized has not advanced significantly since its early days. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based medicine.

We started with the bold objective to reinvent mRNA production, by breaking down barriers from discovery to development, up to commercial production. We focused efforts on the redesign of the production process, its implementation into reagent pre-mixes and plastic disposables, and the automation of that process through low footprint robotized systems for R&D and GMP uses.

After 18 months of dedicated work from the teams at Quantoom Biosciences, we’re delighted to launch Ntensify™ for RNA production.

How Ntensify™ was invented

The COVID-19 pandemic demonstrated the power of RNA vaccines. However, the way RNA is synthesized has not advanced significantly since its early days. Until now, there has not been a simple, scalable and cost-efficient way to produce RNA-based medicine.

We started with the bold objective to reinvent mRNA production, by breaking down barriers from discovery to development, up to commercial production. We focused efforts on the redesign of the production process, its implementation into reagent pre-mixes and plastic disposables, and the automation of that process through low footprint robotized systems for R&D and GMP uses.

After 18 months of dedicated work from the teams at Quantoom Biosciences, we’re delighted to launch Ntensify™ for RNA production.

If you're interested in our Ntensify™ technology Line, don't hesitate to reach out to our BD team.

Contact Us

Please complete the form below for any commercial, partnering, media, press, or general inquiries.

If you need to contact our customer service team, please click on the button below.

5B1A6761_OPT
black-up-orange